{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Platinum-Resistant+Fallopian+Tube+Carcinoma&page=4",
    "query": {
      "condition": "Platinum-Resistant Fallopian Tube Carcinoma",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 126,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Platinum-Resistant+Fallopian+Tube+Carcinoma&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Platinum-Resistant+Fallopian+Tube+Carcinoma&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T01:36:16.047Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03608618",
      "title": "Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Peritoneal Mesothelioma",
        "Fallopian Tube Adenocarcinoma",
        "Adenocarcinoma of the Ovary",
        "Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "MCY-M11",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "MaxCyte, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2018-08-27",
      "completion_date": "2021-08-24",
      "has_results": false,
      "last_update_posted_date": "2021-09-05",
      "last_synced_at": "2026-10-08T01:36:16.047Z",
      "location_count": 4,
      "location_summary": "Rockville, Maryland • Boston, Massachusetts • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03608618"
    },
    {
      "nct_id": "NCT01283035",
      "title": "A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Sarcoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Akt Inhibitor MK2206",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 6,
      "start_date": "2011-04",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2016-06-24",
      "last_synced_at": "2026-10-08T01:36:16.047Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Newton, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Newton",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01283035"
    },
    {
      "nct_id": "NCT06690775",
      "title": "CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Primary Peritoneal",
        "Fallopian Tube Cancer",
        "Endometrioid Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "TORL-1-23",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim (drug)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TORL Biotherapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 230,
      "start_date": "2024-11-20",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-10-08T01:36:16.047Z",
      "location_count": 26,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06690775"
    },
    {
      "nct_id": "NCT05985655",
      "title": "Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma (HNSCC)",
        "Pancreatic Adenocarcinoma",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)",
        "Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma",
        "Triple Negative Breast Cancer (TNBC)"
      ],
      "interventions": [
        {
          "name": "GTAEXS617",
          "type": "DRUG"
        },
        {
          "name": "SoC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2023-07-06",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-08T01:36:16.047Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Grand Rapids, Michigan • New York, New York + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05985655"
    },
    {
      "nct_id": "NCT02440425",
      "title": "Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2015-10-20",
      "completion_date": "2021-05-27",
      "has_results": true,
      "last_update_posted_date": "2022-10-07",
      "last_synced_at": "2026-10-08T01:36:16.047Z",
      "location_count": 3,
      "location_summary": "Tampa, Florida • Durham, North Carolina • Richmond, Virginia",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02440425"
    },
    {
      "nct_id": "NCT01681368",
      "title": "Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Peritoneal Neoplasms",
        "Fallopian Tube Neoplasms"
      ],
      "interventions": [
        {
          "name": "Birinapant (TL32711)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2012-08-15",
      "completion_date": "2014-04-30",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-10-08T01:36:16.047Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01681368"
    },
    {
      "nct_id": "NCT05891197",
      "title": "A Biomarker Screening Protocol for Participants With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Non-small Cell Lung Cancer",
        "Non Small Cell Lung Cancer",
        "Non Small Cell Lung Cancer Metastatic",
        "Non-Small Cell Carcinoma of Lung, TNM Stage 4",
        "Advanced Breast Cancer",
        "Advanced Lung Carcinoma",
        "NSCLC",
        "NSCLC, Recurrent",
        "NSCLC Stage IV",
        "Relapsed Cancer",
        "Relapse/Recurrence",
        "Recurrent Breast Cancer",
        "Recurrent NSCLC",
        "Platinum-resistant Ovarian Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Carcinoma",
        "Fallopian Tube Cancer",
        "Endometrial Cancer",
        "Endometrioid Tumor",
        "High Grade Serous Carcinoma",
        "Ovarian Epithelial Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Lyell Immunopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 10,
      "start_date": "2023-05-19",
      "completion_date": "2025-02-05",
      "has_results": false,
      "last_update_posted_date": "2025-07-01",
      "last_synced_at": "2026-10-08T01:36:16.047Z",
      "location_count": 1,
      "location_summary": "Rocky Mount, North Carolina",
      "locations": [
        {
          "city": "Rocky Mount",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05891197"
    },
    {
      "nct_id": "NCT02631876",
      "title": "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Primary Peritoneal Carcinoma",
        "Fallopian Tube Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Mirvetuximab soravtansine",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pegylated liposomal doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunoGen, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 366,
      "start_date": "2016-03-02",
      "completion_date": "2020-01",
      "has_results": true,
      "last_update_posted_date": "2020-10-14",
      "last_synced_at": "2026-10-08T01:36:16.047Z",
      "location_count": 53,
      "location_summary": "Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 44 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02631876"
    },
    {
      "nct_id": "NCT01952249",
      "title": "A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Demcizumab",
          "type": "DRUG"
        },
        {
          "name": "Taxol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoMed Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 90 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2013-08-05",
      "completion_date": "2016-07-12",
      "has_results": false,
      "last_update_posted_date": "2020-09-09",
      "last_synced_at": "2026-10-08T01:36:16.047Z",
      "location_count": 3,
      "location_summary": "Oklahoma City, Oklahoma • Philadelphia, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01952249"
    },
    {
      "nct_id": "NCT03907527",
      "title": "Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Ovarian Carcinoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Refractory Fallopian Tube Carcinoma",
        "Refractory Ovarian Carcinoma",
        "Refractory Primary Peritoneal Carcinoma",
        "Stage III Fallopian Tube Cancer AJCC V8",
        "Stage III Ovarian Cancer AJCC V8",
        "Stage III Primary Peritoneal Cancer AJCC V8",
        "Stage IIIA Fallopian Tube Cancer AJCC V8",
        "Stage IIIA Ovarian Cancer AJCC V8",
        "Stage IIIA Primary Peritoneal Cancer AJCC V8",
        "Stage IIIA1 Fallopian Tube Cancer AJCC V8",
        "Stage IIIA1 Ovarian Cancer AJCC V8",
        "Stage IIIA2 Fallopian Tube Cancer AJCC V8",
        "Stage IIIA2 Ovarian Cancer AJCC V8",
        "Stage IIIB Fallopian Tube Cancer AJCC V8",
        "Stage IIIB Ovarian Cancer AJCC V8",
        "Stage IIIB Primary Peritoneal Cancer AJCC V8",
        "Stage IIIC Fallopian Tube Cancer AJCC V8",
        "Stage IIIC Ovarian Cancer AJCC V8",
        "Stage IIIC Primary Peritoneal Cancer AJCC V8",
        "Stage IV Fallopian Tube Cancer AJCC V8",
        "Stage IV Ovarian Cancer AJCC V8",
        "Stage IV Primary Peritoneal Cancer AJCC V8",
        "Stage IVA Fallopian Tube Cancer AJCC V8",
        "Stage IVA Ovarian Cancer AJCC V8",
        "Stage IVA Primary Peritoneal Cancer AJCC V8",
        "Stage IVB Fallopian Tube Cancer AJCC V8",
        "Stage IVB Ovarian Cancer AJCC V8",
        "Stage IVB Primary Peritoneal Cancer AJCC V8"
      ],
      "interventions": [
        {
          "name": "PRGN-3005 UltraCAR-T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Precigen, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 71,
      "start_date": "2019-04-30",
      "completion_date": "2028-11-15",
      "has_results": false,
      "last_update_posted_date": "2024-11-08",
      "last_synced_at": "2026-10-08T01:36:16.047Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Seattle, Washington",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03907527"
    }
  ]
}